文献速递冠心病

微轴流泵与梗死相关心源性休克的肾脏结局:DanGer Shock 试验二次分析

Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.
PubMed 文献 · Circulation · 2024-10-27

该研究为 DanGer Shock 试验的预设二次分析,纳入 355 例 ST 段抬高型心肌梗死相关心源性休克患者,随机接受微轴流泵(mAFP)或标准治疗。结果显示 mAFP 组急性肾损伤(AKI)和肾脏替代治疗(RRT)发生率均更高,但 mAFP 降低 180 天死亡率的效果不受 AKI 或 RRT 发生影响。

要点

  • mAFP 组 AKI 发生率 61%,对照组 45%(P<0.01)。
  • mAFP 组 RRT 使用率 42%,对照组 27%(P<0.01)。
  • mAFP 降低 180 天死亡率,与是否发生 AKI 或 RRT 无关(Pinteraction=0.84)。

核心结论

  • 休克严重程度、mAFP 分配及装置相关并发症与 AKI 风险增加相关。
  • AKI 总体与更高死亡率相关,但无论是否发生 AKI 或启动 RRT,mAFP 均一致降低 180 天死亡率。

研究设计与样本

  • 国际、随机、开放标签、多中心试验的预设二次分析。
  • 355 例成人 ST 段抬高型心肌梗死相关心源性休克患者,随机分为 mAFP 组(n=179)或单纯标准治疗组(n=176)。
  • AKI 按 RIFLE 标准定义并使用逻辑回归模型评估;RRT 使用采用 Fine-Gray 竞争风险模型评估。

主要发现

  • AKI(RIFLE ≥1)在 mAFP 组为 110 例(61%),对照组为 79 例(45%)(P<0.01)。
  • RRT 在 mAFP 组为 75 例(42%),对照组为 47 例(27%)(P<0.01)。
  • 约三分之二的 RRT 在入院 24 小时内启动(mAFP 组 n=48 [64%],对照组 n=31 [66%])。
  • AKI 和 RRT 的发生与两组更高的 180 天死亡率相关;180 天时所有存活患者均无需 RRT。
  • mAFP 使用与更高 RRT 率相关,即使考虑死亡竞争风险(子分布风险比 1.67 [1.18-2.35]),该关联在预设亚组中基本一致。

关键数值与推荐

  • AKI 定义采用 RIFLE 标准(风险、损伤、衰竭、丧失和终末期肾病)。
  • mAFP 组 AKI 发生率 61%,对照组 45%(P<0.01);RRT 使用率分别为 42% 和 27%(P<0.01)。
  • mAFP 降低 180 天死亡率与 AKI 或 RRT 的交互作用 P=0.84。

临床怎么用

  • 对于 STEMI 相关心源性休克患者,使用 mAFP 时需警惕 AKI 和 RRT 风险增加。
  • mAFP 降低 180 天死亡率的获益不受 AKI 或 RRT 发生影响,临床决策时可综合考虑。
  • 两组中 AKI 的预测因素包括左室射血分数降低、基线肾功能、休克严重程度、出血事件和正液体平衡;mAFP 特异的预测因素包括吸引事件、更高泵速和更长支持时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed. METHODS: In this international, randomized, open-label, multicenter trial, 355 adult patients with ST-segment-elevation myocardial infarction-related cardiogenic shock were randomized to mAFP (n=179) or standard care alone (n=176). AKI was defined according to RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage kidney disease) and assessed using logistic regression models. Use of RRT was assessed accounting for the competing risk of death using Fine-Gray subdistribution hazard models. RESULTS: AKI (RIFLE ≥1) was recorded in 110 patients (61%) in the mAFP group and 79 patients (45%) in the control group (P<0.01); RRT was used in 75 (42%) and 47 (27%) patients, respectively (P<0.01). About two-thirds of the RRTs were initiated within the first 24 hours from admission (n=48 [64%] in the mAFP group and n=31 [66%] in the control group). Occurrence of AKI and RRT were associated with higher 180-day mortality in both study arms. At 180 days, all patients alive were free of RRT. mAFP use was associated with higher rates of RRT, even when accounting for competing risk of death (subdistribution hazard, 1.67 [1.18-2.35]). This association was largely consistent among prespecified subgroups. Allocation to mAFP was associated with lower 180-day mortality irrespective of AKI or RRT (Pinteraction=0.84). Relevant predictors of AKI in both groups comprised reduced left ventricular ejection fraction, baseline kidney function, shock severity, bleeding events, and positive fluid balance. Predictors of AKI specific to mAFP were suction events, higher pump speed, and longer duration of support. CONCLUSIONS: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01633502.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zweck, Hassager, Beske, et al. Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial. Circulation. 2024. PMID: 39462276. doi:10.1161/CIRCULATIONAHA.124.072370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。